Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephroticrange proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (Clinical Kidney Journal (sfaa225) DOI: 10.1093/ckj/sfaa225)

CARMELINA Investigators

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’

Original languageEnglish (US)
Pages (from-to)2136
Number of pages1
JournalClinical Kidney Journal
Volume14
Issue number9
DOIs
StatePublished - Sep 1 2021

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint

Dive into the research topics of 'Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephroticrange proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (Clinical Kidney Journal (sfaa225) DOI: 10.1093/ckj/sfaa225)'. Together they form a unique fingerprint.

Cite this